Skip to content
OpenCapital
Get started

Orchestra BioMed Holdings, Inc. OBIO Q4 2025 Annual earnings

Reported March 12, 2026 · Before market open

Revenue$30.9MBeat by $30.0M
EPS$0.26Beat by $0.64
Revenue estimate$931.0K
EPS estimate-$0.38

Next report

Aug 11, 2026 (In 1 week)
Revenue estimate$137.7K
EPS estimate-$0.39

Versus estimates

Revenue

Q1 2026$110.0KMiss by $808.7K
Q4 2025$30.9MBeat by $30.0M
Q3 2025$861.0KBeat by $119.6KQ2 2025$836.0KBeat by $57.2KQ1 2025$253.0KMiss by $269.3KQ4 2024$253.0K

Diluted EPS

Q1 2026-$0.33Beat by $0.07
Q4 2025$0.26Beat by $0.64
Q3 2025-$0.40Miss by $0.02Q2 2025-$0.50Beat by $0.01Q1 2025-$0.43In lineQ4 2024-$0.37Beat by $0.06

Ask the moment Orchestra BioMed Holdings, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Orchestra BioMed Holdings, Inc. report Q4 2025 earnings?
Orchestra BioMed Holdings, Inc. (OBIO) reported Q4 2025 earnings on March 12, 2026 before market open.
What were Orchestra BioMed Holdings, Inc.'s Q4 2025 revenue and EPS?
Orchestra BioMed Holdings, Inc. reported revenue of $30.9M and eps of $0.26 for Q4 2025.
Did Orchestra BioMed Holdings, Inc. beat estimates in Q4 2025?
Revenue beat the consensus estimate of $931.0K by $30.0M. EPS beat the consensus estimate of $-0.38 by $0.64.
How did Orchestra BioMed Holdings, Inc.'s Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 12120.2% from $253.0K a year earlier.
Where can I find Orchestra BioMed Holdings, Inc.'s Q4 2025 SEC filings?
You can read the 10-K periodic report (0001104659-26-026754) directly on SEC EDGAR. The filing index links above go to sec.gov.